BioCryst gets a big boost from its lat­est HAE da­ta, but it still faces a dan­ger­ous high wire act and gi­ant ri­vals

A lit­tle more than a year ago, shares of Re­search Tri­an­gle Park, NC-based BioCryst $BCRX were crushed by a failed Phase II tri­al for their lead drug for hered­i­tary an­gioede­ma, or HAE. Set­backs like that are not new for BioCryst. But the biotech turned to an­oth­er HAE drug com­ing up the pipeline. And on Thurs­day, re­searchers de­tailed their sec­ond in­ter­im da­ta re­view of the drug, and won a 31% spike for their stock with an over­all pos­i­tive take on the mid-stage da­ta.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER